专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US4140761A Modification of hepatitis B virus infection in chronic carriers of hepatitis B surface antigen 失效
标题翻译：乙型肝炎病毒感染乙型肝炎表面抗原慢性携带者的修改
公开(公告)号：US4140761A
公开(公告)日：1979-02-20
申请号：US786202
申请日：1977-04-11
申请人： John L. Gerin , Hilton B. Levy , Thomas C. Merigan , Robert H. Purcell , William S. Robinson
发明人： John L. Gerin , Hilton B. Levy , Thomas C. Merigan , Robert H. Purcell , William S. Robinson
IPC分类号： A61K38/21 , A61K45/02 , A61K39/12 , A61K39/42 , A61K45/04
CPC分类号： A61K31/70 , A61K38/21 , Y10S514/889
摘要： Interferon introduced parenterally in a human host or stimulated by an inducer (PICLC) for a period of greater than 21 days results in a major decrease in all markers of infectivity, such as DNA polymerase, and such markers remain at a depressed level during the period of treatment. Where PICLC is utilized to induce interferon in the host, a serum level of 50 units per milliliter or higher is necessary for effective clinical treatment and 17 .times. 10.sup.4 - 6.0 .times. 10.sup.3 U/kg/day is an effective dose for exogenous interferon. Especially long-term treatment with exogenous interferon of greater than 21 days and up to 14 months results in clinical improvement for chronic hepatitis B virus (HBV) infection and this long-term treatment has resulted in sustained improvement even after cessation of treatment as well as resulting in a decrease in infectivity risk to others in close proximity to the infected human host. Such clinical improvement is marked by normalization of liver histology.
摘要翻译：干扰素肠胃外引入人宿主或由诱导物（PICLC）刺激大于21天的时间导致所有传染性标志物如DNA聚合酶的显着降低，并且这些标记在该期间保持在沮丧的水平的治疗。在PICLC用于诱导宿主中的干扰素的情况下，对于有效的临床治疗需要50单位/ ml或更高的血清水平，而对于外源性干扰素，17×104-6.0×10 3 U / kg /天是有效剂量。特别是长期治疗21天以上14个月以外的外源性干扰素可导致慢性乙型肝炎病毒（HBV）感染的临床改善，长期治疗即使在治疗停止后也能持续改善，导致受感染的人类宿主附近的其他人感染风险降低。这种临床改善的特征是肝组织学正常化。

2. 再颁专利

USRE38352E1 Polymerase chain reaction assays for monitoring antiviral therapy and making therapeutic decisions in the treatment of acquired immunodeficiency syndrome 有权
标题翻译：用于监测抗病毒治疗的聚合酶链反应测定法，并在治疗获得性免疫缺陷综合征中作出治疗决定
公开(公告)号：USRE38352E1
公开(公告)日：2003-12-16
申请号：US10236326
申请日：2002-09-05
申请人： Michael J. Kozal , Thomas C. Merigan
发明人： Michael J. Kozal , Thomas C. Merigan
IPC分类号： C12Q170
CPC分类号： C12Q1/703 , C12Q2600/106 , C12Q2600/156
摘要： The present invention relates to methods of monitoring, via polymerase chain reaction, the clinical progression of human immunodeficiency virus infection and its response to antiretroviral therapy. According to the invention, polymerase chain reaction assays may be used to predict immunological decline and to identify, at an early stage, patients whose infection has become resistant to a particular antiretroviral drug regimen.

3. 发明授权

US5314800A Purified human cytomegalovirus protein 失效
标题翻译：纯化人巨细胞病毒蛋白
公开(公告)号：US5314800A
公开(公告)日：1994-05-24
申请号：US17509
申请日：1993-02-12
申请人： Lucy E. Rasmussen , Thomas C. Merigan
发明人： Lucy E. Rasmussen , Thomas C. Merigan
IPC分类号： A61K39/00 , C07K14/045 , C07K16/08 , C12N5/20 , C12Q1/70 , C07K3/18
CPC分类号： C07K16/088 , C07K14/005 , A61K39/00 , C12N2710/16122 , Y10S530/806 , Y10S530/826
摘要： A purified human CMV virion protein that has a molecular weight of approximately 86,000 daltons by SDS-PAGE and exhibits in vivo. immunizing activity and a murine monoclonal antibody that binds specifically to the protein and exhibits complement-independent human CMV neutralizing activity are described. The antibody is useful for isolating the protein by affinity chromatography and the protein is, in turn, useful for detecting CMV neutralizing antibody in sera and as a vaccine.
摘要翻译：纯化的人CMV病毒粒子蛋白，通过SDS-PAGE具有约86,000道尔顿的分子量，并在体内显示。描述了免疫活性和与蛋白质特异性结合并表现出与补体无关的人CMV中和活性的鼠单克隆抗体。该抗体可用于通过亲和层析分离蛋白质，并且蛋白质又可用于检测血清和疫苗中的CMV中和抗体。

4. 发明授权

US06503705B2 Polymerase chain reaction assays for monitoring antiviral therapy and making therapeutic decisions in the treatment of acquired immunodeficiency syndrome 失效
公开(公告)号：US06503705B2
公开(公告)日：2003-01-07
申请号：US09782971
申请日：2001-02-13
申请人： Michael J. Kozal , Thomas C. Merigan , David A. Katzenstein , Mark Holodniy
发明人： Michael J. Kozal , Thomas C. Merigan , David A. Katzenstein , Mark Holodniy
IPC分类号： C12Q170
CPC分类号： C12Q1/703 , C12Q2600/106 , C12Q2600/156
摘要： The present invention relates to methods of monitoring, via polymerase chain reaction, the clinical progression of human immunodeficiency virus infection and its response to antiretroviral therapy. According to the invention, polymerase chain reaction assays may be used to predict immunological decline and to identify, at an early stage, patients whose infection has become resistant to a particular antiretroviral drug regimen.

5. 发明授权

US5968730A Polymerase chain reaction assays for monitoring antiviral therapy and making therapeutic decisions in the treatment of acquired immunodeficiency syndrome 失效
公开(公告)号：US5968730A
公开(公告)日：1999-10-19
申请号：US470885
申请日：1995-06-06
申请人： Thomas C. Merigan , David A. Katzenstein , Mark Holodniy
发明人： Thomas C. Merigan , David A. Katzenstein , Mark Holodniy
IPC分类号： C12Q1/70 , C12Q1/68
CPC分类号： C12Q1/703 , C12Q2600/106 , C12Q2600/156
摘要： The present invention relates to methods of monitoring, via polymerase chain reaction, the clinical progression of human immunodeficiency virus infection and its response to antiretroviral therapy. According to the invention, polymerase chain reaction assays may be used to predict immunological decline and to identify, at an early stage, patients whose infection has become resistant to a particular antiretroviral drug regimen.

6. 发明授权

US5194256A Purified human cytomegalovirus protein 失效
标题翻译：纯化人巨细胞病毒蛋白
公开(公告)号：US5194256A
公开(公告)日：1993-03-16
申请号：US104392
申请日：1987-10-02
申请人： Lucy E. Rasmussen , Thomas C. Merigan
发明人： Lucy E. Rasmussen , Thomas C. Merigan
IPC分类号： A61K39/00 , C07K14/045 , C07K16/08 , C12N5/20
CPC分类号： C07K16/088 , C07K14/005 , A61K39/00 , C12N2710/16122 , Y10S530/806 , Y10S530/826
摘要： A purified human CMV virion protein that has a molecular weight of approximately 86,000 daltons by SDS-PAGE and exhibits in vivo immunizing activity and a murine monoclonal antibody that binds specifically to the protein and exhibits complement-independent human CMV neutralizing activity are described. The antibody is useful for isolating the protein by affinity chromatography and the protein is, in turn, useful for detecting CMV neutralizing antibody in sera and as a vaccine.
摘要翻译：描述了通过SDS-PAGE分析量约86,000道尔顿并显示出体内免疫活性的纯化人CMV病毒粒子蛋白，以及特异性结合蛋白质并显示出与补体无关的人CMV中和活性的鼠单克隆抗体。该抗体可用于通过亲和层析分离蛋白质，并且蛋白质又可用于检测血清和疫苗中的CMV中和抗体。

7. 发明授权

US4743562A Purified human cytomegalovirus protein 失效
标题翻译：纯化人巨细胞病毒蛋白
公开(公告)号：US4743562A
公开(公告)日：1988-05-10
申请号：US642828
申请日：1984-08-21
申请人： Lucy E. Rasmussen , Thomas C. Merigan
发明人： Lucy E. Rasmussen , Thomas C. Merigan
IPC分类号： A61K39/00 , C07K14/045 , C07K16/08 , C12N5/00 , A61K39/245 , A61K39/42 , C12N15/00
CPC分类号： C07K16/088 , C07K14/005 , A61K39/00 , C12N2710/16122 , Y10S435/948
摘要： A purified human CMV virion protein that has a molecular weight of approximately 86,000 daltons by SDS-PAGE and exhibits in vivo immunizing activity and a murine monoclonal antibody that binds specifically to the protein and exhibits complement-independent human CMV neutralizing activity are described. The antibody is useful for isolating the protein by affinity chromatography and the protein is, in turn, useful for detecting CMV neutralizing antibody in sera and as a vaccine.
摘要翻译：描述了通过SDS-PAGE分析量约86,000道尔顿并显示出体内免疫活性的纯化人CMV病毒粒子蛋白，以及特异性结合蛋白质并显示出与补体无关的人CMV中和活性的鼠单克隆抗体。该抗体可用于通过亲和层析分离蛋白质，并且蛋白质又可用于检测血清和疫苗中的CMV中和抗体。

8. 发明授权

US07129041B2 Polymerase chain reaction assays for monitoring antiviral therapy and making therapeutic decisions in the treatment of acquired immunodeficiency syndrome 失效
公开(公告)号：US07129041B2
公开(公告)日：2006-10-31
申请号：US10321162
申请日：2002-12-16
申请人： Thomas C. Merigan , David A. Katzenstein , Mark Holodniy
发明人： Thomas C. Merigan , David A. Katzenstein , Mark Holodniy
IPC分类号： C12Q1/70 , C12Q1/68 , C12P19/34 , C12M1/34 , C07H21/04
CPC分类号： C12Q1/703 , C12Q2600/106 , C12Q2600/156
摘要： The present invention relates to methods of monitoring, via polymerase chain reaction, the clinical progression of human immunodeficiency virus infection and its response to antiretroviral therapy. According to the invention, polymerase chain reaction assays may be used to predict immunological decline and to identify, at an early stage, patients whose infection has become resistant to a particular antiretroviral drug regimen.

9. 发明授权

US5650268A Polymerase chain reaction assays for monitoring antiviral therapy and making therapeutic decisions in the treatment of acquired immunodeficiency syndrome 失效
公开(公告)号：US5650268A
公开(公告)日：1997-07-22
申请号：US471072
申请日：1995-06-06
申请人： Michael J. Kozal , Thomas C. Merigan
发明人： Michael J. Kozal , Thomas C. Merigan
IPC分类号： C12Q1/70 , C12Q1/68
CPC分类号： C12Q1/703 , C12Q2600/106 , C12Q2600/156
摘要： The present invention relates to methods of monitoring, via polymerase chain reaction, the clinical progression of human immunodeficiency virus infection and its response to antiretroviral therapy. According to the invention, polymerase chain reaction assays may be used to predict immunological decline and to identify, at an early stage, patients whose infection has become resistant to a particular antiretroviral drug regimen.

10. 发明授权

US5631128A Polymerase chain reaction assays for monitoring antiviral therapy and making therapeutic decisions in the treatment of acquired immunodeficiency syndrome 失效
标题翻译：用于监测抗病毒治疗的聚合酶链反应测定法，并在治疗获得性免疫缺陷综合征中作出治疗决定
公开(公告)号：US5631128A
公开(公告)日：1997-05-20
申请号：US290311
申请日：1994-08-15
申请人： Michael J. Kozal , Thomas C. Merigan
发明人： Michael J. Kozal , Thomas C. Merigan
IPC分类号： C12Q1/70 , C07H21/04 , C12P19/34 , C12Q1/68
CPC分类号： C12Q1/703 , C12Q2600/106 , C12Q2600/156
摘要： The present invention relates to methods of monitoring, via polymerase chain reaction, the clinical progression of human immunodeficiency virus infection and its response to antiretroviral therapy. According to the invention, polymerase chain reaction assays may be used to predict immunological decline and to identify, at an early stage, patients whose infection has become resistant to a particular antiretroviral drug regimen.
摘要翻译：本发明涉及通过聚合酶链反应监测人类免疫缺陷病毒感染的临床进展及其对抗逆转录病毒治疗的应答的方法。根据本发明，可以使用聚合酶链反应测定来预测免疫学下降，并且在早期鉴定其感染已经变得对特定抗逆转录病毒药物方案具有抗性的患者。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式